Radiotherapy Dose Escalation in Unresectable Ewing’s Sarcoma/ PNET: Final Results of a Phase III Randomized Controlled Trial
Sarbani Ghosh Laskar(Tata Memorial Hospital), Purna Kurkure(SRCC Children’s Hospital), Ambarish Chatterjee(Tata Memorial Hospital), Tushar Vora(Tata Memorial Hospital), Bharat Rekhi(Homi Bhabha National Institute), Venkatesh Rangarajan(Tata Memorial Hospital), Girish Chinnaswamy(Tata Memorial Hospital), Shwetabh Sinha(Homi Bhabha National Institute), M.A. Muckaden(Homi Bhabha National Institute), Prakash Nayak(Tata Memorial Hospital), Sanket Shah(Tata Memorial Hospital), Maya Prasad(Tata Memorial Hospital), Ajay Puri(Homi Bhabha National Institute), Niharika Khanna(Tata Memorial Hospital), Ashish Gulia(Tata Memorial Hospital), Nilendu Purandare(Tata Memorial Hospital), N. A. Jambhekar(Tata Memorial Hospital), Sangeeta Desai(Tata Memorial Hospital), S Juvekar(Tata Memorial Hospital), Amit Janu(Tata Memorial Hospital)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2019
Cited by 6
Related Papers
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis
|European Journal of Nuclear Medicine and Molecular Imaging|2011|377
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
|Journal of Clinical Oncology|2017|340
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
|Journal of Clinical Oncology|2021|338